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Abstract
Purpose Positron emission tomography (PET) using 18F-3′-
deoxy-3′-fluorothymidine ([18F]FLT) allows noninvasive
monitoring of tumour proliferation. For serial imaging in
individual patients, good reproducibility is essential. The
purpose of the present study was to evaluate the reproduc-
ibility of quantitative [18F]FLT measurements.
Methods Nine patients with non-small-cell lung cancer
(NSCLC) and six with head-and-neck cancer (HNC)
underwent [18F]FLT PET twice within 7 days prior to
therapy. The maximum pixel value (SUVmax) and a
threshold defined volume (SUV41%) were defined for all
delineated lesions. The plasma to tumour transfer constant
(Ki) was estimated using both Patlak graphical analysis and
nonlinear regression (NLR). NLR was also used to estimate
k3, which, at least in theory, selectively reflects thymidine
kinase 1 activity. The level of agreement between test and
retest values was assessed using the intraclass correlation
coefficient (ICC) and Bland-Altman analysis.
Results All primary tumours and >90% of clinically
suspected locoregional metastases could be delineated. In
total, 24 lesions were defined. NLR-derived Ki, Patlak-
derived Ki, SUV41% and SUVmax showed excellent
reproducibility with ICCs of 0.92, 0.95, 0.98 and 0.93,
and SDs of 16%, 12%, 7% and 11%, respectively.
Reproducibility was poor for k3 with an ICC of 0.43 and
SD of 38%.
Conclusion Quantitative [18F]FLT measurements are repro-
ducible in both NSCLC and HNC patients. When monitor-
ing response in individual patients, changes of more than
15% in SUV41%, 20–25% in SUVmax and Patlak-derived
Ki, and 32% in NLR3k-derived Ki are likely to represent
treatment effects.
Keywords Positron emission tomography .
Non-small-cell lung cancer . Reproducibility . FLT
Introduction
18F-3′-Deoxy-3′-fluorothymidine ([18F]FLT) has been pro-
posed as a positron emission tomography (PET) tracer of
proliferation. FLT is a substrate for thymidine kinase 1
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(TK1), which is a key enzyme in the salvage pathway of
thymidine DNA synthesis. Several studies have shown
good correlations between [18F]FLT uptake and other
markers of cellular proliferation, including proliferating
cell nuclear antigen, flow cytometry and Ki-67 nuclear
staining [1–5].
In most tumours [18F]FLT uptake is lower than [18F]
FDG uptake [6]. In addition, its biodistribution and
metabolic profile are not ideal [7]. Consequently, [18F]
FDG PET remains the method of choice for diagnosing and
staging of tumours. It has been suggested that [18F]FLT
may have additional value in combination with [18F]FDG
because the combination has been reported to result in
fewer false-positive findings [8, 9], but results have not
been consistent [2, 10, 11].
Based on its TK1-related signal, [18F]FLT PET has been
proposed as a biomarker for predicting (early) response to
systemic or locoregional treatment [12–14]. Recent studies
have shown that [18F]FLT PET can predict response to
therapy as early as 1 week after treatment [15], and a
decrease in [18F]FLT uptake seems to be correlated with
prolonged overall survival [16, 17].
In addition, [18F]FLT might also be a specific tracer for
monitoring the effects of agents targeting thymidylate
synthase (TS), an enzyme that plays a central role in the
de novo pathway of DNA synthesis. Downregulation of
this pathway results in an upregulation of the salvage
pathway and thus of [18F]FLT uptake. Recent results have
indicated that anti-TS effects can be monitored as soon as
2 hours after administration [18].
To evaluate response in individual patients, reproduc-
ibility of the parameter of interest needs to be known. The
purpose of the present study was to determine reproduc-
ibility of quantitative [18F]FLT measurements in a prospec-
tive study of patients with non-small-cell lung cancer
(NSCLC) or head-and-neck cancer (HNC).
Materials and methods
Eligible patients were included prospectively after provid-
ing written informed consent in accordance with institu-
tional review board approval. In total, nine patients with
NSCLC and six with HNC were scanned twice within
7 days (mean 1.9 days, median 1 day) prior to any therapy
using an ECAT EXACT HR+ scanner (Siemens/CTI,
Knoxville, TN). This scanner has an axial field of view
(FOV) of 15 cm, divided into 63 contiguous planes. Each
patient was positioned supine on the scanner bed with the
primary tumour in the centre of the axial FOV. The primary
tumour and all other evaluable lesions in the FOV were
analysed. A venous catheter was placed in all patients,
which was used for injection of [18F]FLT and venous blood
sampling [19]. In addition, in HNC patients an arterial
catheter was placed in the radial artery for arterial blood
sampling. Each acquisition started with a 10 to 15-min
transmission scan in order to acquire a fixed number of 85
million counts [20], which was used for attenuation
correction of the subsequent emission scan. This was
followed by a bolus injection of 370 MBq [18F]FLT in
5 ml saline through an injector (Medrad International,
Maastricht, The Netherlands) at 0.8 ml/s, after which the
line was flushed with 42 ml saline (2.0 ml/s). Simulta-
neously with the injection of [18F]FLT, a dynamic emission
scan (in 2-D acquisition mode) was started with a total
duration of 60 min and with variable frame lengths (6×5 s,
6×10 s, 3×20 s, 5×30 s, 5×60 s, 8×150 s, and 6×300 s). All
dynamic scan data were corrected for dead time, decay,
scatter, randoms and photon attenuation, and were recon-
structed as 128×128 matrices using filtered back projection
(FBP) with a Hanning filter (cut-off, 0.5 cycles per pixel).
This resulted in a transaxial spatial resolution of around
7 mm full-width at half-maximum (FWHM). As FBP
reconstructed images suffer from streak artefacts, volume
of interest (VOI) definition may be inaccurate, especially in
lesions with low tumour-to-background contrast [21, 22].
Therefore, for VOI definition purposes only, the last three
frames of the sinograms (45–60 min after injection) were
summed and reconstructed using ordered-subset expecta-
tion maximization (OSEM) with two iterations and 16
subsets followed by postsmoothing of the reconstructed
images using a 5-mm FWHM gaussian filter to obtain the
same resolution as for the FBP images [21].
In the HNC patients, arterial 18F concentrations were
monitored continuously using a fully automated blood
sampling device (Veenstra Instruments, Joure, The Nether-
lands) [23]. The withdrawal rate was 5 ml/min during the
first 10 min and 2.5 ml/min thereafter. In all patients,
venous blood samples were drawn at 5, 10, 20, 30, 40 and
60 min after injection to correct for plasma/whole blood
ratios and plasma metabolite fractions, and as a quality
control procedure for defining an image-derived input
function (IDIF) for NSCLC patients as described for [18F]
FDG [24]. To avoid contamination, 3–5 ml blood was
withdrawn prior to each sample and the line was flushed
with 1.5 ml saline after sampling, as described previously
[19].
Venous blood samples were analysed using solid-phase
extraction chromatography for separation of [18F]FLT from
[18F]FLT glucuronide. For this procedure 0.3 ml plasma was
dissolved in 2 ml water. This solution was placed onto a
SepPak Vac 6cc (1 g) C18 cartridge (Waters Corporation,
Milford, MA). The eluate was collected, after which the
cartridge was rinsed with 5 ml water to collect the polar
metabolites, being primarily [18F]FLT-glucuronide. The
cartridge was then rinsed with 5 ml 96% ethanol to collect
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the parent compound. All fractions and the cartridge were
counted using a Wallac 1480 Wizard well counter (Perkin-
Elmer Life Science, Zaventem, Belgium), and the percentage
parent within each plasma sample calculated. Metabolite
data were interpolated by fitting to an exponential function.
Image analysis
The maximum pixel value within the tumour and a
threshold defined volume (41% of the maximum pixel
value with correction for local background) were defined
semiautomatically for any lesion with adequate focal uptake
[25, 26]. Boundaries of lesions without adequate tumour-to-
background contrast (low focal uptake and/or high level of
background) are difficult to define and, consequently,
delineation is hampered by increased observer variation.
Therefore, only lesions which required no or only minor
manual delineation were included. In the latter case
background values were set to zero for voxels directly
adjacent to the VOI that had a physiologically high
radiotracer concentration (hypervascular areas, haemato-
poietic bone marrow and liver). After this procedure the
threshold technique was applied, resulting in volumes
specifically containing tumour. Tumour VOIs were defined
on OSEM reconstructed images and transferred to FBP
reconstructed dynamic images, thereby generating time–
activity curves (TACs). An input function was obtained by
continuous arterial blood sampling in HNC patients and
derived from the dynamic FBP images in NSCLC patients.
IDIFs were defined by multiple manually drawn 2-D
regions of interest (ROIs) over the aortic arch (elliptical
ROI, 8×30 mm) and ascending aorta (spherical ROI,
15 mm) [27]. Again, ROIs were then projected onto all
frames to generate input TACs.
Data analysis
Full kinetic analysis to derive values of the individual rate
constants and Ki, the plasma to tumour transfer constant, was
performed for threshold defined VOIs using the following
methods: (1) Patlak graphical analysis (time interval 10–
60 min after injection; Ki only) [28] and (2) nonlinear
regression (NLR) using the standard two-tissue compartment
model with both three (NLR3k) and four (NLR4k) rate
constants and an additional blood volume parameter (Vb). In
both cases, the metabolite-corrected plasma curve was used
as input function. The presence of a fourth rate constant
(representing dephosphorylation of phosphorylated [18F]
FLT) and the need to include this in the model were assessed
by comparing fits with and without a k4 parameter using
Akaike [29] and Schwarz [30] criteria.
Kinetic analysis of regional tissue TACs was performed
using dedicated software developed within Matlab (The
Mathworks, Natick, MA). In general, fits are rejected when
the (fitted) standard error of any parameter exceeds 25%.
This was, however, never the case in the present study. In
addition, the goodness of fit was checked visually for all
TACs. SUV was derived for both the maximum pixel value
(SUVmax) and the threshold defined VOI (SUV41%) for the
time intervals 40–60 min and 50–60 min after injection
(with multiple correction factors [31]). The level of
agreement between test and retest values was assessed
using the intraclass correlation coefficient (ICC) with a
two-way random model with absolute agreement, and
Bland-Altman analysis [32]. In the latter case, the percent-
age difference in values (Δ) between two measures was
plotted against (1) the mean of both measures and (2) the
mean threshold defined volume. In this way, possible
dependency on both absolute [18F]FLT uptake and tumour
size could be evaluated. Additionally, dependency was
statistically analysed using linear regression. Finally, a one-
sample t test was applied to the Δ values to assess
systematic bias and the parameter values of both test and
retest scans were compared using the Wilcoxon signed
ranks test to evaluate the distribution.
Results
All primary tumours and more than 90% of clinically
suspected locoregional metastases could be delineated. In
total, 24 lesions (15 NSCLC and 9 HNC) were defined. A
small subset of lesions (5/24) required manual intervention
during delineation (Fig. 1). Full kinetic analysis was
possible for 23 lesions; blood analyses failed in one patient.
The median lesion size (threshold defined PET volume)
was 8.2 cm3 (range 1.7–86.1 cm3), the median NLR3k-
derived Ki was 0.047 ml·min
−1·ml−1 (range 0.021–
0.120 ml·min−1·ml−1), the median Patlak-derived Ki was
0.037 ml·min−1·ml−1 (range 0.017–0.074 ml·min-1·ml-1),
the median SUV41% was 3.3 (range 1.3–6.4) and the
median SUVmax was 4.8 (range 2.4–9.3). The 3k model
provided better fits than the 4k model in 26 (57%) and 28
(61%) of 46 measured lesions according to Akaike and
Schwarz criteria, respectively. In other words, the majority
of the data were best fitted with the 3k model. Visual check
of the TACs revealed good fits for all lesions.
Descriptive statistics for all parameters of [18F]FLT
kinetics for both test and retest scans, as well as p values for
the Wilcoxon signed ranks test, are presented in Table 1.
No systematic bias (one-sample t test: SUV41%, p=0.98;
Patlak Ki, p=0.25), or a significant difference in the
distribution of paired differences (Wilcoxon signed ranks
test; p>0.08 for all) was found. The threshold VOI
definition technique resulted in consistent volumes for most
tumours throughout both scans. The median change in
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tumour volume between test and retest scans was 10%.
Only the delineation of one lesion resulted in an excep-
tional difference in volume of 150% between the two scans.
This was probably due to inaccurate definition of the
maximum pixel value, possibly caused by patient motion in
one or both scans.
Only very small variations were found between different
SUV41% normalization methods (body weight, body surface
area and lean body mass) and time intervals (40–60 min
and 50–60 min after injection) with ICCs ranging from 0.97
to 0.98. Therefore, the SUV results are presented for only
one correction method (body weight) and a single time
interval (40–60 min after injection). NLR3k-derived Ki,
Patlak-derived Ki, SUV41% and SUVmax showed excellent
reproducibility with ICCs of 0.92, 0.95, 0.98 and 0.93, and
SDs of 16%, 12%, 7% and 11%, respectively (Table 2). In
contrast, NLR3k-derived k3, which, at least in theory,
selectively reflects TK1 activity, showed poor reproducibility
with an ICC of 0.43 and an SD of 38%. As expected from
Akaike and Schwarz analyses, inclusion of a fourth rate
constant resulted in decreased reproducibility with an ICC of
0.75 and an SD of 25% for NLR4k-derived Ki, and an ICC
of 0.33 and an SD of 70% for NLR4k-derived k3 (Table 2).
These data show that, when monitoring therapy effects,
changes of less than 32% in NLR3k-derived Ki, 24% in
Patlak-derived Ki, 14% in SUV41% and 22% in SUVmax
(<1.96×SD) cannot be distinguished from normal test–
retest variability.
Subgroup analysis for NSCLC and HNC patients
showed similar results for Patlak-derived Ki and an even
better SD result for NLR3k-derived Ki in NSCLC patients
as compared to HNC patients, suggesting no error due to
the use of an IDIF (Table 2).
Bland-Altman plots of SUV41% and Patlak-derived Ki
showed no dependency on absolute [18F]FLT uptake, but a
trend of reduced reproducibility for smaller lesions (Fig. 2).
This trend, however, was not statistically significant
(SUV41%, p=0.35; Patlak Ki, p=0.51).
Discussion
Our results show that quantitative [18F]FLT measurements
are reproducible in both NSCLC and HNC patients. When
serial measurements in patients are performed, changes of
more than 15% in SUV41%, 20–25% in Patlak-derived Ki
and SUVmax, and 30–35% in NLR3k-derived Ki are likely
to represent biological effects. In addition, no significant
dependency between absolute [18F]FLT uptake and lesion
size was found, implying that the same threshold can be
used for all tumour lesions. Although one tumour lesion
showed a change of 150% in tumour volume between the
Table 1 Descriptive statistics of mean and median values, standard deviation and range for all parameters of [18F]FLT kinetics of both scans
Test scan Retest scan
Parameter Mean Median SD Range No. of
measurements
Mean Median SD Range No. of
measurements
p value (Wilcoxon
signed ranks test)
NLR3k Ki 0.048 0.042 0.021 0.022–0.120 24 0.047 0.042 0.018 0.021–0.101 23 0.73
NLR3k K1 0.177 0.139 0.128 0.076–0.608 24 0.159 0.142 0.076 0.087–0.393 23 0.86
NLR3k k2 0.118 0.109 0.067 0.030–0.360 24 0.102 0.087 0.052 0.041–0.257 23 0.65
NLR3k k3 0.047 0.044 0.019 0.017–0.104 24 0.043 0.042 0.015 0.020–0.079 23 0.33
NLR3k Vb 0.153 0.109 0.143 0.013–0.608 24 0.123 0.114 0.100 0.001–0.394 23 0.17
Patlak Ki
a 0.038 0.036 0.013 0.019–0.072 24 0.039 0.037 0.015 0.017–0.074 23 0.32
SUV41%
b 3.35 3.28 1.11 1.42–6.42 24 3.35 3.20 1.12 1.34–6.23 24 0.79
SUVmax
b 5.17 5.14 1.63 2.66–9.32 24 5.04 4.78 1.66 2.40–9.22 24 0.17
VOI sizec 16.5 8.4 20.1 1.6–82.4 24 18.5 9.4 21.8 1.8–89.8 24 0.08
a Patlak analysis was performed using the time interval 10–60 min after injection.
b SUV values presented were corrected for body weight and measured between 40 and 60 min after injection.
c VOI size is tumour volume in cubic centimetres, defined by a 41% threshold technique as described in the text.
a bFig. 1 Two coronal [
18F]FLT
images of tumour lesions that
required manual intervention.
a Lesion in the right upper lobe
close to a costal bone.
b Large intrapulmonary lesion
with inferior part close to the
right diaphragm
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two scans, the threshold technique resulted in reproducible
tumour volumes for all other lesions.
Akaike and Schwarz analyses showed that for most
tumour lesions data were best fitted with the 3k model,
indicating that [18F]FLT phophorylation was irreversible, at
least within the time frame of the measurements. Therefore,
the fourth rate constant should be set to zero. In a recent
study it was shown that significant dephosphorylation starts
at ±50 min after injection and that k4 can reliably be
estimated with a scan time of 120 min [33]. Furthermore, a
strong correlation was found between NLR3k Ki derived
from a 60-min scan and NLR4k Ki derived from a 120-min
scan [33]. A scan protocol of 120 min, however, is too long
for routine (serial) clinical studies, especially in critically ill
patients. In addition, the risk of movement artefacts increases
with longer scan times. Our results indicate that with a scan
time of 60 min, a fourth rate constant can be neglected.
To the best of our knowledge, reproducibility of [18F]
FLT measurements in malignant tumours has only been
assessed in eight patients (nine lesions) with breast cancer
[15] and in six patients with NSCLC [34]. Shields et al.
[34] evaluated an unknown number of lesions in six
patients using SUVmax and SUVmean (50% threshold
technique) and carried out full kinetic analyses (NLR with
a b
c d
Fig. 2 Bland-Altman plots for SUV41% and Patlak Ki (circles NSCLC
lesions, triangles NHC lesions, delta values percentage change
between test and retest scans, SUV41% and SUVmax for the time
interval 40–60 min after injection and corrected for body weight,
Patlak Patlak-derived Ki, mean PET volume mean threshold defined
volume of the test and retest scan in cm3, straight lines mean values,
dotted lines ±1.96×SD)
Table 2 Reproducibility results of simplified and full kinetic analyses of [18F]FLT uptake
Patients ICC (95% CI) SD percentage change SD absolute change
NLR3k Ki All 0.92 (0.83–0.97) 16 0.008
NLR3k k3 All 0.43 (0.30–0.71) 38 0.019
NLR3k Vb All 0.81 (0.60–0.92) 35 0.040
NLR4k Ki All 0.75 (0.49–0.88) 25 0.016
NLR4k k3 All 0.33 (-0.95–0.65) 70 0.073
Patlak Ki All 0.95 (0.89–0.98) 12 0.004
SUV41% All 0.98 (0.95–0.99) 7 0.2
SUVmax All 0.93 (0.85–0.97) 11 0.6
NLR3k Ki NSCLC 0.92 (0.78–0.98) 11 0.004
Patlak Ki NSCLC 0.92 (0.75–0.97) 12 0.004
NLR3k Ki HNC 0.92 (0.72–0.98) 22 0.011
Patlak Ki HNC 0.96 (0.85–0.99) 12 0.005
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unknown number of rate constants and Patlak) with the use
of an IDIF. Unfortunately, full details of their study (e.g. the
number of rate constants in the NLR analyses, location and
number of lesions, whether mean or median for absolute
difference of test and retest scans) were not reported.
Nevertheless, reproducibility results were comparable with
the present results (around 20% test–retest variability in
SUV and kinetic parameters).
Results in breast cancer [15] are also consistent with the
present results with reported ICCs of 0.99 and 0.97, and SDs
of 11% and 15% for SUV and Patlak Ki, respectively.
Differences in study design and methods, however, make it
difficult to perform a direct comparison. The absence of
IDIF analyses, the relatively low number of lesions included
with no locoregional (lymph node) metastases, and the very
high tumour-to-background ratio in the breast (due to low
uptake of [18F]FLT in fatty tissue) [35, 36] imply that results
for breast tumours do not necessarily hold for tumours of
other origins (with lower tumour-to-background ratio).
In the present study IDIF was used for NSCLC lesions,
thereby greatly simplifying the acquisition protocol for
thoracic tumours. Clearly, this is much more convenient for
patients and better suited for routine clinical use. Subgroup
analyses for NLR3k and Patlak-derived Ki did not reveal
inferior results for NSCLC as compared to HNC, where
arterial blood sampling was performed, suggesting that the
use of an IDIF does not significantly contribute to test–
retest variability.
In the present analyses, locoregional lymph nodes were
also included, and thereby all possible scenarios encoun-
tered in clinical trials were evaluated. In addition, this
provided a means for evaluating possible dependency on
absolute [18F]FLT value and tumour size.
SUVmax is the most frequently used (semi)quantitative
measure in clinical PET studies due to its ease of definition
and low observer variation. Nevertheless, results indicate
that better reproducibility can be achieved by using
threshold defined SUV41%. Although pulmonary lesions
are not easy to delineate due to physiologically high uptake
in surrounding mediastinum, liver, vertebrae and costal
bones, reproducibility was not reduced, indicating that the
applied threshold technique is reliable.
Since radiotracer uptake depends on perfusion and
extraction, SUV and Ki are not specific measurements of
TK1 activity. [18F]FLT uptake mainly depends on the
extracellular ATP concentration, which has greatest impact
on the turnover of [18F]FLT due to induction of a change in
structure of TK1 from a dimer to a tetramer, which has
about a 20-fold greater effect on the turnover of the tracer
[37]. However, previous data have shown that [18F]FLT
uptake may also depend on perfusion (blood flow) rather
than on TK1 activity [38]. Therefore, at least in theory, k3
appears to be the parameter of interest for studying TK1
activity. Unfortunately, NLR3k-derived k3 showed poor
reproducibility. However, both Ki and SUV have shown
good correlations with other proliferation markers, with Ki
having the strongest correlation [4, 15, 33]. The present
results indicate that both Ki and SUV are reproducible.
Since Ki has the best correlation with other proliferation
markers, dynamic scanning should, whenever possible, be
applied in response monitoring studies. If static scans are
acquired, however, the present results support the use of a
threshold defined VOI instead of the maximum pixel value.
In the present study only therapy-naive tumours were
analysed. It should be kept in mind, however, that an
intervention may affect the various rate constants in a
different manner. For example, a certain therapy could result
in a reduction in delivery (K1) with only a minor change in
TK1 activity (k3). In that case, both Ki and SUV would
decrease more than the actual decrease in proliferation rate.
In addition, SUV and Ki might not be similarly affected.
Conclusion
Our results show that both simplified and full kinetic
analyses of [18F]FLT data have excellent reproducibility in
NSCLC and HNC patients. Furthermore, the data support
the use of an IDIF for kinetic analyses of intrathoracic
lesions. Future response monitoring studies, correlating
[18F]FLT response with pathological and clinical outcome,
should be performed to assess which [18F]FLT parameter is
best for predicting response to therapy.
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